Aequs Limited IPO Review
Neutral118-124 · Mainboard
✦
Analyst Verdict
Aequs Limited IPO
Neutral
IPO at a Glance
Price Band
118-124
Issue Size
921cr
Min. Investment
₹14,880
Opens
2025-12-01
Closes
2025-12-03
Listing
2025-12-08
Category
Mainboard
Key Strengths
✓Vertically integrated aerospace ecosystem offering end-to-end manufacturing.
✓Strong global presence with facilities in India, France, and the U.S.
✓Long-term relationships with major global OEMs across aerospace and consumer segments.
✓Proven capability across machining, forging, surface treatment, plastics, toys, and electronics.
✓Large, scalable cluster-based manufacturing setup enabling cost and delivery efficiency.
Key Risks
⚠High dependence on the aerospace sector and a limited number of large customers.
⚠Exposure to global economic cycles, geopolitical risks, and supply-chain disruptions.
⚠Significant working capital and capital expenditure requirements.
⚠Foreign exchange fluctuations may impact revenues and margins.
⚠Any production delays or quality issues could affect customer contracts and reputation.
Frequently Asked Questions
Should I apply for Aequs Limited IPO?
Based on our analysis, our rating for Aequs Limited IPO is: Neutral. Review the full analysis including strengths, risks, and financials on CheckIPO before making a decision.
What are the key risks of Aequs Limited IPO?
High dependence on the aerospace sector and a limited number of large customers. Exposure to global economic cycles, geopolitical risks, and supply-chain disruptions. Significant working capital and capital expenditure requirements.
What are the strengths of Aequs Limited IPO?
Vertically integrated aerospace ecosystem offering end-to-end manufacturing. Strong global presence with facilities in India, France, and the U.S. Long-term relationships with major global OEMs across aerospace and consumer segments.
What is the price band of Aequs Limited IPO?
The price band for Aequs Limited IPO is 118-124. The IPO has closed.
Full Analysis Available
Financials, DRHP breakdown, peer comparison, shareholding pattern & more